Penile Cancer

{{header-clinical-trials-navigation}}

Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy


Condition: Penile Squamous Cell Carcinoma

Intervention:

  • Drug: Pembrolizumab

Purpose: Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the investigational agent for this penile cancer study.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02837042

Sponsor: University of Alabama at Birmingham

Primary Outcome Measures:

  • Measure: Objective tumor response rate
  • Time Frame: Baseline up to two years
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Duration of response and stable disease
  • Time Frame: From the first treatment up to two years
  • Safety Issue:
  • Measure: Progression-free survival
  • Time Frame: Baseline up to two years
  • Safety Issue:
  • Measure: Overall survival
  • Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
  • Safety Issue:
  • Measure: Number of adverse events
  • Time Frame: Baseline up to two years
  • Safety Issue:

Estimated Enrollment: 35

Study Start Date: October 2016

Phase: Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • 1. Locally advanced unresectable or metastatic stage 4 (i.e. T4 or N3 or M1) PSCC 2. Radiologic evidence for progressive disease after ≥1 prior chemotherapy regimen 3. Be at least 18 years of age on day of signing informed consent. 4. Have measurable disease based on RECIST 1.1. 5. Have a performance status of 0-2 on the ECOG (Eastern Cooperative Oncology Group) Performance Scale. 6. Demonstrate adequate organ function with all screening labs being performed within 14 days of treatment initiation.
  • Absolute neutrophil count (ANC) ≥1,500 /mcL
  • Platelets ≥100,000/mcL
  • Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or erythropoietin dependency (within 7 days of assessment)
  • Serum creatinine ≤1.5 X upper limit of normal (ULN); alternately measured or calculated creatinine clearance ≥30 mL/min with creatinine levels >1.5 X institutional ULN (GFR can also be used in place of creatinine or CrCl)
  • Serum total bilirubin ≤1.5 X ULN or direct bilirubin ≤ ULN for subjects with total bilirubin levels >1.5 ULN
  • AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN or ≤ 5 X ULN for subjects with liver metastases
  • Albumin >2.5 mg/dL
  • International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants 7. Subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy 8. Formalin-fixed paraffin embedded (FFPE) tumor tissue from previous biopsy is requested, but not mandatory. 9. Be willing and able to provide written informed consent/assent for the trial.

Exclusion Criteria:

  • 1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. 2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. 3. Has a known history of active TB (Bacillus Tuberculosis) 4. Hypersensitivity to Pembrolizumab or any of its excipients. 5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. 6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.
  • Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
  • Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. 7. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. 8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability. 9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 10. Has known history of, or any evidence of active, non-infectious pneumonitis. 11. Has an active infection requiring systemic therapy. 12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 14. Is pregnant expecting to father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. 15. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. 16. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 17. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). 18. Has known active Tuberculosis infection. 19. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Contact:

  • Lisle Nabell, MD
  • 205-934-3061

Locations:

  • University of Alabama at Birmingham
  • Birmingham Alabama 35294 United States
  • University of Southern California
  • Los Angeles California 90033 United States
  • Winship Cancer Institute at Emory University
  • Atlanta Georgia 30322 United States

View trial on ClinicalTrials.gov


{{footer-clinical-trials-navigation}}
{{header-clinical-trials-navigation}}

A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy


Condition: Penile Squamous Cell Carcinoma (PSCC)

Intervention:

  • Drug: Gilotrif

Purpose: Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by regulatory agencies. This study will evaluate the drug Gilotrif in patients with metastatic progressive PSCC following chemotherapy. Gilotrif has shown supportive evidence in non-small cell lung cancer by inhibiting certain proteins that are also found in PSCC. The drug has the potential for some patients to exhibit a response contributing to a greater quality of life.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02541903

Sponsor: University of Alabama at Birmingham

Primary Outcome Measures:

  • Measure: Progression free survival
  • Time Frame: 6 months following study treatment
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Response rate
  • Time Frame: Baseline up to 18 months
  • Safety Issue:
  • Measure: Overall survival
  • Time Frame: Baseline to death (assessed up to 30 months).
  • Safety Issue:
  • Measure: Toxicities
  • Time Frame: Baseline up to 18 months
  • Safety Issue:

Estimated Enrollment: 29

Study Start Date: October 2015

Phase: Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • 1. Histologically or cytologically confirmed PSCC. 2. Patients with metastatic or locally advanced unresectable PSCC. 3. Progressive disease after ≥1 prior chemotherapy regimens. 4. Measurable disease by RECIST 1.1 criteria. 5. Prior regimen within 6 months 6. ECOG performance status 0-2. 7. Adequate organ function, defined as all of the following:
  • Absolute neutrophil count (ANC) >1500 /mm3. Platelet count >100,000/ mm3.
  • Estimated creatinine clearance ≥ 45ml/min.
  • Total Bilirubin <1.5 times upper limit of institutional normal; Aspartate amino transferase (AST) or alanine amino transferase (ALT) <2.5 times the upper limit of institutional normal (ULN).
  • Hemoglobin ≥8.5 g/dl. 8. Resolution of all acute toxic effects of prior chemotherapy or surgical procedures to NCI CTCAE version 4.03 grade <1, in the opinion of the Treating Physician. 9. Ability to understand and willingness to sign a written informed consent. Age ≥18 years or age of majority at the participating site, whichever is greater. 10. Availability of 20 archival formalin-fixed paraffin embedded tumor tissue slides.

Exclusion Criteria:

  1. Patients will have recovered from toxicities from prior systemic anticancer treatment or local therapies.
  2. Prior EGFR inhibitors.
  3. Major surgery within 4 weeks or minor surgery within 2 weeks before registration or scheduled for surgery during the projected course of the study. Wounds will be completely healed prior to study entry and patients recovered from all toxicities from surgery. Placement of vascular access device is not considered major or minor surgery in this regard.
  4. Prior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least 3 weeks prior to enrollment. If the irradiated area is the only site of disease, there will be progressive disease.
  5. History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior to registration.
  6. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug.
  7. Previous or concomitant malignancies at other sites, except effectively treated non-melanoma skin cancers, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.
  8. Requiring treatment with any of the prohibited concomitant medications listed in the protocol that cannot be stopped for the duration of trial participation.
  9. Known pre-existing interstitial lung disease.
  10. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption).
  11. Active hepatitis B infection (defined as presence of Hep BsAg and/ or Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV carrier.
  12. Meningeal carcinomatosis.
  13. Patients with active brain or subdural metastases are not eligible, unless they have completed local (radiation) therapy and have discontinued the use of corticosteroids or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to brain metastases will be stable for at least 4 weeks before starting study treatment.
  14. Any active or uncontrolled infection.

Contact:

  • Pam Dixon, BSN, OCN
  • 205-975-5387

Locations:

  • University of Alabama at Birmingham
  • Birmingham Alabama 35294 United States
  • University of Southern California
  • Los Angeles California 90033 United States
  • MD Anderson Cancer Center
  • Houston Texas 77030 United States

View trial on ClinicalTrials.gov


{{footer-clinical-trials-navigation}}
{{header-clinical-trials-navigation}}

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)


Condition: Squamous Cell Carcinoma of the Penis, Usual Type

Intervention:

  • Procedure: ILND - Inguinal Lymph Node Dissection
  • Drug: Paclitaxel
  • Drug: Ifosfamide
  • Drug: Cisplatin
  • Radiation: Intensity modulated radiation treatment (IMRT)
  • Procedure: Prophylactic PLND - pelvic lymph node dissection

Purpose: This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions. InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of three initial treatments: A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND); or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND). After ILND, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ILND specimen. Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02305654

Sponsor: Institute of Cancer Research, United Kingdom

Primary Outcome Measures:

  • Measure: Overall survival
  • Time Frame: up to 5 years
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Disease specific survival time
  • Time Frame: up to 5 years
  • Safety Issue:
  • Measure: Number of patients experience a grade 3 or 4 toxicity
  • Time Frame: up to 5 years
  • Safety Issue:
  • Measure: Disease-free survival time
  • Time Frame: up to 5 years
  • Safety Issue:
  • Measure: Occurrence of surgical complication
  • Time Frame: up to 5 years
  • Safety Issue:
  • Measure: Is it possible to achieve pathological nodal assessment after chemotherapy
  • Time Frame: 12 weeks
  • Safety Issue:
  • Measure: Quality of life
  • Time Frame: Baseline, 3, 6, 9, 12, 18, 24 and 36 months
  • Safety Issue:
  • Measure: Occurrence of Pathological complete remission
  • Time Frame: Time to complete remission after randomisation
  • Safety Issue:
  • Measure: Operability
  • Time Frame: 2-6 weeks
  • Safety Issue:
  • Measure: Occurrence of Lower limb/scrotal oedema
  • Time Frame: up to 5 years
  • Safety Issue:
  • Measure: On-schedule delivery of neoadjuvant therapy
  • Time Frame: After randomisation up to 12 weeks
  • Safety Issue:

Estimated Enrollment: 400

Study Start Date: May 12, 2017

Phase: Phase 3

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • 1. Written informed consent 2. Measurable disease as determined by RECIST (version 1.1) criteria; 3. Histologically-proven squamous cell carcinoma of the penis, 4. Stage:
  • any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0 or;
  • any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0 or;
  • any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0 5. Performance Status ECOG 0, 1 or 2.

Exclusion Criteria:

  1. Pure verrucous carcinoma of the penis,
  2. Nonsquamous malignancy of the penis,
  3. Squamous carcinoma of the urethra,
  4. Stage M1,
  5. Previous chemotherapy or chemoradiotherapy,
  6. Concurrent malignancy (other than SCC or Basal Cell Carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 3 years.

Contact:

  • InPACT Senior Trial Manager
  • 02087224261

Locations:

  • The Royal Marsden NHS Foundation Trust
  • London SM2 5PT United Kingdom
  • St George's Hospital NHS Foundation Trust
  • London SW17 0QT United Kingdom

View trial on ClinicalTrials.gov


{{footer-clinical-trials-navigation}}
{{header-clinical-trials-navigation}}

HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers


Condition: Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma

Intervention:

  • Genetic: HPV Specific T Cells
  • Drug: Cytoxan
  • Drug: Fludarabine
  • Biological: Nivolumab

Purpose: Subjects have a type of cancer that has been associated with an infection with a virus called human papilloma virus (HPV). The cancer has come back, has not gone away after standard treatment or the subject cannot receive standard treatment. This is a research study using special immune system cells called HPVST cells, a new experimental treatment. Investigators want to find out if they can use this type of treatment in patients with HPV-cancers. They have discovered a way to grow large number of HPV-specific T cells from the blood of patients with HPV-cancers. They want to see if these special white blood cells, called HPVST cells, that will have been trained to kill HPV infected cells can survive in the blood and affect the tumor. They will also see if they can make the T cells more active against the HPV-cancers by engineering them to be resistant to the TGF-beta chemical that these HPV-cancers produce. They will grow these HPVST cells from the patient's blood. The purpose of this study is to find the biggest dose of HPVSTs that is safe, to see how long they last in the body, to learn what the side effects are and to see if the HPVSTs will help people with HPV associated cancers. If the treatment with HPVST cells alone proves safe (Group A), additional group of patients (Group B) will receive Nivolumab in addition to HPVST cells in a lymphodepleted environment. Nivolumab is an antibody therapy that helps T cells control the tumor and it is FDA approved for the treatment of certain types of cancers, including Hodgkin's lymphoma. Lymphodepletion will decrease the level of circulating T cells prior to infusion of HPVST cells, thereby giving them room to expand. The purpose of this part of the study is to find out if TGF-beta resistant HPVST cells in combination with Nivolumab are safe, how long they last in the body and if they are more effective than HPVST cells alone in controlling the tumor.

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02379520

Sponsor: Baylor College of Medicine

Primary Outcome Measures:

  • Measure: Number of patients with dose limiting toxicity (DLT)
  • Time Frame: 6 weeks
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Overall response rate
  • Time Frame: 6 weeks
  • Safety Issue:

Estimated Enrollment: 32

Study Start Date: September 2015

Phase: Phase 1

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  • PROCUREMENT 1. Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample 2. Cancer is:
  • recurrent or persistent after standard therapy
  • OR patient is unable to receive standard therapy 3. Karnofsky score ≥ 50% 4. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent TREATMENT 1. Diagnosis of a cancer for which the presence of a high risk HPV type has been documented in a biopsy sample 2. Cancer is:
  • recurrent or persistent after standard therapy
  • OR patient is unable to receive standard therapy 3. Life expectancy ≥ 6 weeks. 4. Age ≥ 18 years. 5. Karnofsky score ≥ 50% 6. Bilirubin < 3 × upper limit of normal (ULN), AST < 5 × ULN, Hgb ≥ 7.0 g/dL 7. Pulse oximetry of > 90% on room air. 8. GFR > 30 mL/min calculated by the Cockcroft-Gault, MDRD study, or CKD-EPI creatinine equations, or equivalent 9. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent 10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.

Exclusion Criteria:

  1. PROCUREMENT
  2. Known HIV positivity. TREATMENT
  3. Currently receiving any investigational agents or have received any tumor vaccines or T cell antibodies within previous 4 weeks.
  4. Severe intercurrent infection.
  5. Pregnancy or lactation.

Contact:

  • Carlos Ramos, MD
  • 832-824-4817

Location:

  • Houston Methodist Hospital
  • Houston Texas 77030 United States

View trial on ClinicalTrials.gov


{{footer-clinical-trials-navigation}}
{{header-clinical-trials-navigation}}

Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors


Condition: Various Advanced Cancer

Intervention:

  • Drug: Nivolumab
  • Drug: Ipilimumab
  • Drug: Relatlimab
  • Drug: Daratumumab

Purpose: The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: - Anal canal cancer-No longer enrolling this tumor type - Cervical cancer - Epstein Barr Virus (EBV) positive gastric cancer-No longer enrolling this tumor type - Merkel Cell Cancer - Penile cancer-No longer enrolling this tumor type - Vaginal and vulvar cancer-No longer enrolling this tumor type - Nasopharyngeal Cancer - No longer enrolling this tumor type - Head and Neck Cancer - No longer enrolling this tumor type

Study Type: Interventional

Clinical Trials Identifier NCT 8-digits: NCT02488759

Sponsor: Bristol-Myers Squibb

Primary Outcome Measures:

  • Measure: The safety and tolerability will be measured by the incidence of drug-related adverse events (AEs) and serious adverse events (SAEs)
  • Time Frame: 6 months after the last patient receives their first dose
  • Safety Issue:
  • Measure: Objective response rate
  • Time Frame: 6 months after the last patient receives their first dose
  • Safety Issue:
  • Measure: Rate of surgery delay
  • Time Frame: 6 months after the last patient receives their first dose
  • Safety Issue:

Secondary Outcome Measures:

  • Measure: Progression-free survival
  • Time Frame: Approximately 3 years
  • Safety Issue:
  • Measure: Overall survival
  • Time Frame: Approximately 3 years
  • Safety Issue:
  • Measure: Duration of response
  • Time Frame: Approximately 3 years
  • Safety Issue:

Estimated Enrollment: 1100

Study Start Date: October 8, 2015

Phase: Phase 1/Phase 2

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: All

Inclusion Criteria:

  • Histopathologic confirmation of the following tumor types (please refer to protocol for full details pertaining to eligible tumor types): 1. Merkel Cell Carcinoma 2. Gastric or Gastro-Esophageal junction carcinoma (No longer enrolling this tumor type) 3. Nasopharyngeal Carcinoma 4. Squamous cell carcinoma (SCC) of the cervix, vagina, or vulva 5. Squamous cell carcinoma of the Head and Neck 6. Squamous cell carcinoma of the anal canal and penis 7. Recurrent/metastatic SCC of the cervix not amenable to curative treatment with surgery and/or radiation therapy who are unsuitable for platinum-based therapy may enroll in the cervical cancer Combination B expansion cohort
  • Measurable disease by CT or MRI
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Patient willing to comply to provide tumor tissue (archival or fresh biopsy specimen)
  • Men and women of age 18 or older

Exclusion Criteria:

  • Active brain metastases or leptomeningeal metastases
  • Patients with active, known or suspected autoimmune disease
  • Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
  • Patients with hepatitis
  • Patients with HIV
  • Pregnant or breastfeeding women

Contact:

  • Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:

Locations:

  • H. Lee Moffitt Cancer Center
  • Tampa Florida 33612-9497 United States
  • Winship Cancer Institute
  • Atlanta Georgia 30322 United States
  • Local Institution
  • New Orleans Louisiana 70121 United States
  • Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
  • Lutherville Maryland 21093 United States
  • Dana-Farber Cancer Institute
  • Boston Massachusetts 02114 United States
  • Massachusetts General Hospital
  • Boston Massachusetts 02114 United States
  • Beth Israel Desc. Med Ctr
  • Boston Massachusetts 02215 United States
  • University Of Michigan Comprehensive Cancer Center
  • Ann Arbor Michigan 48109 United States
  • Memorial Sloan-Kettering Cancer Center-Breast Center
  • New York New York 10017 United States
  • Levine Cancer Institute
  • Charlotte North Carolina 28204 United States
  • Stephenson Cancer Center
  • Oklahoma City Oklahoma 73104 United States
  • Providence Portland Medical Center
  • Portland Oregon 97213 United States
  • UPMC Eye and Ear Institute
  • Pittsburgh Pennsylvania 15232 United States
  • Sanford Clinic Clinical Research
  • Sioux Falls South Dakota 57104-4707 United States
  • Seattle Cancer Care Alliance
  • Seattle Washington 98109 United States
  • Local Institution
  • Capital Federal Buenos Aires 1426 Argentina
  • Local Institution
  • Brussels 1000 Belgium
  • Local Institution
  • Brussels 1090 Belgium
  • Local Institution
  • Bruxelles 1200 Belgium
  • Local Institution
  • Marseille Cedex 9 13273 France
  • Local Institution
  • Paris 75475 France
  • Institut Claudius Regaud
  • Toulouse Cedex 9 31059 France
  • Institut Gustave Roussy
  • Vlllejuif 94800 France
  • Local Institution
  • Essen 45147 Germany
  • Local Institution
  • Heidelberg 69120 Germany
  • Local Institution
  • Heilbronn 74078 Germany
  • Local Institution
  • Wuerzburg 97080 Germany
  • Local Institution
  • Kashiwa-shi Chiba 2778577 Japan
  • Local Institution
  • Chuo-ku Tokyo 1040045 Japan
  • Local Institution
  • Koto-ku Tokyo 135-8550 Japan
  • Local Institution
  • Seoul 110-774 Korea, Republic of
  • COI Centro Oncologico Internacional S.A.P.I. de C.V.
  • Ciudad de Mexico Distrito Federal 04700 Mexico
  • Local Institution
  • Oaxaca de Juarez Oaxaca 68040 Mexico
  • Centro de Atencion e Investigacion Clinica en Oncologia SCP
  • Merida Yucatan 97138 Mexico
  • Local Institution
  • Amsterdam 1066 CX Netherlands
  • Local Institution
  • Utrecht 3584 CX Netherlands
  • Local Institution
  • Craiova 200347 Romania
  • H. Univ. Vall dHebron
  • Barcelona 08035 Spain
  • Hospital Madrid Norte Sanchinarro
  • Madrid 28050 Spain
  • Clinica Universidad de Navarra
  • Navarra 31008 Spain
  • Local Institution
  • Tainan 70403 Taiwan
  • Local Institution
  • Taipei 10002 Taiwan
  • Local Institution
  • Glasgow Lanarkshire G12 OYN United Kingdom
  • Local Institution
  • Birmingham WEST Midlands B15 2TH United Kingdom
  • Local Institution
  • London W1T 7HA United Kingdom

View trial on ClinicalTrials.gov


{{footer-clinical-trials-navigation}}
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe